CADILA HEALTHCARE LTD. - 532321 - Clarification
The Exchange had sought clarification from Cadila Healthcare Ltd with reference to the media report, https://economictimes.indiatimes.com/ May 13, 2019, "Pharma stocks bleed as US states file lawsuit against generic drug firms "The company response is enclosed. Cadila Healthcare Ltd - 532321 - Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing on https://economictimes.indiatimes.com May 13, 2019 titled "Pharma stocks bleed as US states file lawsuit against generic drug firms ". The reply is awaited. Zydus Cadila gets USFDA nod for blood pressure lowering drug
The group now has 266 approvals and has filed over 350 ANDAs Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Chlorthalidone Tablets USP CADILA HEALTHCARE LTD. - 532321 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report11/05/2019 3 Name of the Certifying Firm Manoj Hurkat & Associates 4 Name of the Certifying Individual Manoj Hurkat 5Membership TypeACS 6 Membership Number 4287 7 CP No. 2574 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate Cadila Healthcare falls to over four-year low after USFDA inspection
Cadila Healthcare's shares fell as much as 3.6 per cent to Rs 292.85. The stocks had touched a four-year low.The United States Food and Drug Administ Will USFDA observation affect Cadila Healthcare?
Cadila Healthcare on Friday said that the USFDA inspected the company's formulations manufacturing facility located at Moraiya, Ahmedabad, from April CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We hereby inform that the USFDA inspected the Company's formulations manufacturing facility located at Moraiya, Ahmedabad from 22nd April 2019 to 3rd May 2019. The inspection concluded with 14 observations. There were no repeat observations or Data Integrity (DI) related observations. The Company is confident of addressing these observations and responding to the USFDA at the earliest. Please bring the aforesaid news to the notice of the members of the exchange and the investors at large. CADILA HEALTHCARE LTD. - 532321 - Certificate Under Regulation 74(5)
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Period ended March 31, 2019